Bibliography
- Lee JC, Kumar S, Griswold DE, et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000;47:185-201
- Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 1999;5:439-48
- Dodeller F, Schulze-Koops H. The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells. Arthritis Res Ther 2006;205
- Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 2005;12(25):2979-94
- Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Dev 2005;8(4):421-30
- Dambach DM. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 2005;5(10):929-39
- Norman P. Kinase therapeutic pipelines: an assessment of targets and agents in development CHI Insight reports december 2007. p. 71-6
- Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32
- Murali Dhar TG, Wrobleski ST, Lin S, et al. Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds. Bioorg Med Chem Lett 2007;17(18):5019-24
- Hynes J Jr, Dyckman AJ, Lin S, et al. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino) -pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors. J Med Chem 2008;51(1):4-16
- Liu C, Lin J, Pitt S, et al. Benzothiazole based inhibitors of p38alpha MAP kinase. Bioorg Med Chem Lett 2008;18(6):1874-9
- Sack JS, Kish KF, Pokross M, et al. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase. Acta Crystallogr D Biol Crystallogr 2008;D64(Pt 7):705-10
- Hynes J Jr, WU H, Pitt S, et al. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor. Bioorg Med Chem Lett 2008;18(6):1762-7
- Bristol-Myers Squibb Co. Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein. WO2006113682; 2006
- Bristol-Myers Squibb Co. New pyrazole-amide compounds are p38 kinase inhibitors - useful for the treatment of inflammatory disorders. WO2004098518; 2004
- Bristol-Myers Squibb Co. Pyrrolo-triazine aniline compounds useful as kinase inhibitors. WO03090912; 2003